drugset / Trial / NCT05035953

Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke

NCT05035953

RandomizedParallel-groupDouble-blindTreatment

Summary

To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received thrombolysis.

Timeline

Start
2021-09-13
Primary completion
2023-09-13
Completion
2024-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexborneol Small molecule 7.5 mg
Subject Edaravone Unknown 30 mg

Indications